V ascular smooth muscle cells (VSMCs) within adult blood vessels proliferate at a very low rate, exhibit very low synthetic activity, and express a unique repertoire of contractile proteins, ion channels, and signaling molecules. 1 Unlike skeletal muscle and cardiac muscle, which consist of terminally differentiated cells, adult VSMCs retain remarkable plasticity and can undergo rather profound and reversible changes in phenotype and growth properties in response to changes in local environmental cues. Salient examples of VSMC plasticity can be seen in response to vascular injury when VSMCs dramatically increase their proliferation, migration, and synthetic capacity, playing a critical role in vascular repair. 1, 2 A detrimental consequence of the high degree of plasticity exhibited by adult VSMCs is that it can lead to an adverse phenotypic switch and acquisition of characteristics that can contribute to development or progression of vascular disease in humans, including atherosclerosis, restenosis, cancer, and hypertension. [1] [2] [3] VSMC phenotypic modulation is characterized by significant changes in gene expression patterns, matrix and cytokine production, contractility, and growth state, ultimately leading to their switch from a synthetic to a proliferative phenotype.
Thus, understanding the regulatory mechanisms underlying the VSMC phenotypic switch is of paramount importance. [1] [2] [3] One of the key breakthroughs for the study of gene expression regulation has recently been the discovery of microRNAs (miRNAs or miRs) and their role in gene silencing through mRNA degradation or translational inhibition. 4, 5 Increasing evidence indicates that miRNAs regulate key genetic programs in cardiovascular biology, physiology, and disease. 4, 5 In particular, miR-21, -143, -145, -221, -222 have all been implicated to play a role in VSMC function and phenotypic plasticity. 6 -11 More recently, 2 articles demonstrated that miR-1 is induced by myocardin overexpression in human SMCs, contributing to myocardin-dependent reduction of human SMC growth in vitro. 12, 13 miR-133a-1/miR-1-2 and miR133a-2/miR-1-1 are 2 bicistronic miRNA clusters reported to be specifically expressed in cardiac and skeletal muscle. 4, 5 A third bicistronic miRNA cluster, comprising miR-206 and miR-133b, is expressed specifically in skeletal muscle but not in the heart. 4,5 miR-1 (miR-1-1/miR-1-2) and miR-133 (miR133a-1/miR-133a-2) play essential roles in cardiac and skeletal muscle development, physiology, and disease 4, 5 ; however, their functions in VSMCs and vascular disease are largely unknown. Thus, the aim of the present study was to evaluate the role, if any, of miR-1 and miR-133 in VSMC phenotypic switch in vitro and in response to vascular injury in rat carotid arteries in vivo.
Methods
Adenoviruses expressing miR-1 (adeno-miR-1) and miR-133 (adeno-miR-133) were obtained as previously described. 14 Anti-miR constructs were obtained from Ambion (Austin, TX). Balloon injury of the right carotid artery was performed in male Wistar rats using a Fogarty 2F arterial embolectomy catheter as described. 15, 16 miR-133 probe for FISH analysis and the PBS-formulated lockednucleic-acid-modified anti-miR-133 were obtained from Exiqon (Woburn, MA).
An expanded Methods section is available in the online-only Data Supplement at http://circres.ahajournals.org.
Results

miR-1 and miR-133 Regulation in Quiescent and Proliferating VSMCs
miR-1 and miR-133 are significantly more expressed in skeletal and cardiac muscle tissue, compared with aorta, carotid artery, and bronchial SM tissue ( Figure 1A to 1C) . However, miR-1 was almost absent in vascular SM tissue, whereas miR-133 was expressed at levels comparable to those of some vascular enriched miRs, such as miR-221 and miR-222, but lower than those of other vascular miRs, such as miR-143 and miR-145 ( Figure 1D ). FISH analysis demonstrated that in carotid arteries miR-133 is specifically expressed in VSMCs ( Figure 1E and Online Figure I ). The latter was confirmed at the single-cell level analyzing freshly isolated adult aortic VSMCs ( Figure 1E ). miR-133a is mainly expressed in VSMC cytoplasm, whereas miR-133b is not expressed in VSMCs (Online Figure II) .
In serum-starved synchronized quiescent adult rat aortic VSMCs (0.5Ϯ0.5% BrdU pos ), miR-133 was significantly more abundant than miR-1, whereas the latter had indeed almost negligible levels ( Figure 1F ). At the different time points after serum stimulation, miR-1 levels remained unchanged. On the other hand, miR-133 was significantly downregulated in proliferating VSMCs (74.5Ϯ7.5% and 88.5Ϯ8.5% BrdU pos at 24 and 48 hours, respectively), compared with their quiescent counterparts ( Figure 1F ). Cycling VSMCs had very low levels of miR-133 as analyzed by FISH ( Figure 1G ). When proliferating VSMCs were coaxed back into quiescence by serum starvation at 48 hours for a further 48 hours (total 96 hours, 3.5Ϯ2.5% BrdU pos ), mi-R133 transcripts increased back to levels comparable to those of the quiescent state of the baseline experiment at time 0 ( Figure 1F) .
In cardiac and skeletal muscle cells, miR-133 is regulated by several factors, including the MAPKs. 17 The ras/MAPK pathway has a crucial role in promoting VSMC proliferation in vitro and in vivo. 1, 2, 18 In agreement with previous findings, 18 PD98059, a selective inhibitor of MAPK/ERK1/2 kinase, abolished ERK1/2 phosphorylation and VSMC proliferation on PDGF treatment (data not shown). More importantly, PD98059 treatment (50 mol/L) significantly inhibited the PDGF-mediated downregulation of miR-133 in proliferating VSMCs ( Figure 1H ). On the contrary, the inhibition of MAPK/c-Jun N-terminal kinase with SP600125, MAPK/p38 with SB203580, or phosphatidylinositol 3Ј-OH kinase with LY294002 had no significant effect on the downregulation of miR-133 by PDGF (data not shown).
These data show that miR-133, unlike miR-1, is appreciably expressed in vascular SM tissues and cells. Importantly, miR-133 levels show physiological variation during the VSMC cycle by which miR-133 is downregulated in proliferating VSMCs in vitro. Furthermore, ERK1/2 activation is at least in part responsible for miR-133 downregulation when VSMCs are primed for the phenotypic switch in vitro.
miR-133 but Not miR-1 Modulates VSMC Proliferation In Vitro
For miR-133 or miR-1 gain-of-function experiments, VSMC were transfected with adeno-miR-133 or adeno-miR-1. 14 Control cells were transfected with adeno-GFP or adenoempty vectors. The 2 latter adenovectors had no effect per se on VSMC molecular phenotype or growth status compared with naive untransfected control cells, and to simplify the presentation, CTRL label (primarily referring to untransfected control cells) includes these 3 group of controls if not otherwise specified. For loss-of-function experiments, we used chemically modified single stranded nucleic acids designed to specifically bind to and inhibit endogenous miR-133 (anti-miR-133) or miR-1 (anti-miR-1). A random sequence anti-miR molecule (scrambled anti-miR) served as negative control. Anti-miR-133 administration did not affect VSMC proliferation stimulated by 10% FBS (Online Figure IV) . The latter could be related to the extreme reduction of endogenous miR-133 levels in 10% FBS stimulated VSMCs ( Figure 2G ), which cannot be further affected by an additional exogenous inhibition. Indeed, 2% FBS stimulation downregulates miR-133 significantly less than 10% FBS ( Figure 2G ). Remarkably, in the latter conditions, anti-miR-133 treatment significantly increased VSMC proliferation compared with CTRL cells (Figure 2H and 2I) .
Non-standard Abbreviations and Acronyms
miR-1 overexpression, as well as that of anti-miR-1, did not affect VSMC proliferation in vitro ( Figure 2I, 2J and 2K) .
In summary, miR-133, but not miR-1, plays a significant physiological role on VSMC growth in vitro. Preventing miR-133 downregulation on proliferative switch by miR-133 overexpression reduces VSMC proliferation. On the other hand, knocking down miR-133 function increases VSMC proliferation.
Targets of miR-133 in VSMC Activation In Vitro
Searching for evolutionarily conserved targets of miR-133 by TargetScan prediction algorithms, 19 we spotted the transcription factor Sp-1, which regulates VSMC phenotypic switch in vitro and is upregulated in animal models of vascular injury, 20 -22 and the actin-binding protein moesin, which regulates VSMC migration in vitro and in vivo. 23 Adeno-miR-133 caused mRNA degradation of both Sp-1 and moesin, whereas mRNA levels of the latter 2 genes were upregulated when VSMCs were treated with anti-miR-133 ( Figure 3A and 3E). Accordingly, 2 specific luciferase reporters for Sp-1 and moesin were specifically repressed by exogenous miR-133 ( Figure 3D and 3H). Consistent with these findings, expression of Sp-1 and moesin proteins was upregulated in VSMCs treated with anti-miR-133, whereas it was decreased in VSMCs transfected with adeno-miR-133 ( Figure 3B and 3C and F-G). Thus, miR-133 directly targets for repression Sp-1 and moesin in VSMCs in vitro.
We assessed whether rescuing Sp-1 repression by miR-133 prevented miR-133 effects on VSMC proliferation. To this end, we cotransfected VSMCs with a synthetic miR-133 mimic (pre-miR-133 precursor molecule, which, similarly to adeno-miR-133, inhibits VSMC proliferation in vitro [Online Figure V] ) and an Sp-1 cDNA construct mutated in the 3Ј untranslated region binding site for miR-133 seed region (Sp-1 mut ), which cannot be repressed by miR-133. Sp-1 mut overexpression ( Figure 3I ) directly amplified PDGF-BBinduced VSMC proliferation in vitro ( Figure 3J ). More importantly, Sp-1 mut transduction rescued the inhibitory effects on VSMC proliferation in vitro by pre-miR-133 overexpression ( Figure 3J ). Finally, as moesin, as well as Sp-1, modulates VSMC migration, 1, 22, 23 we tested the hypothesis that miR-133 might also inhibit cell migration. On 2% FBS stimulation for 24 hours, adeno-miR-133 transfection resulted in a significant decrease of migrating VSMCs in the Boyden chamber. Accordingly, anti-miR-133 did increase VSMC migration ( Figure 3K ).
miR-133 Regulation of SM Genes In Vitro
SRF, which belongs to the MADS (MCMI, Agamous, Deficiens, SRF) transcription factor family, is known to regulate numerous cardiac, skeletal, and SM genes binding with the CArG [a CC(AT) 6 GG motif] elements 1,3 through its potent transcriptional coactivator, myocardin. 24 Importantly, SRF is a known target for transcriptional repression by miR-1/133, while at the same time, SRF regulates miR-1/133 transcription. 4, 5 Also, the hearts of miR-133a-1/miR-133a-2 double knockout mice are characterized by a number of upregulated genes encoding SM-restricted proteins. 19 On this premise, we first evaluated the direct effects of miR-133 gain (adeno-miR-133 transfection) and loss of function (anti-miR-133) on mRNA and protein levels of 5 SM genes: calponin (CNN1), transgelin-1 (TAGLN1), and -2 (TAGLN2), ␣-SM actin (also called ACTA2) and SM myosin heavy chain (MYH11 or SM-myosin heavy chain). Accordingly, miR-133 effects on SRF and myocardin expression levels were also evaluated.
miR-133 overexpression decreased the transcript levels of Cnn1, Tagln2, and Acta2, but it actually increased the transcripts of Myh11 ( Figure 4A ). Also, adeno-miR-133 had no effect on Tagln1 mRNA ( Figure 4A ). It is worth noting here that TAGLN2 is not an SMC-restricted gene, as it is more broadly expressed than TAGLN1, whereas MYH11 is the most specific gene to identify SMCs. 1 These mixed effects at the mRNA level of these SM genes by miR-133 were accompanied by a decrease or increase of the correspondent protein levels ( Figure 4B ). Accordingly, anti-miR-133 increased mRNA and protein levels of CNN1, TAGLN2 and ACTA2, and it decreased mRNA and protein levels of MYH11 ( Figure 4A and 4B) .
Furthermore, miR-133 overexpression reduced SRF mRNA and protein levels, whereas the opposite effects were fostered by the anti-miR-133 ( Figure 4C and 4D) . Finally, miR-133 does not directly regulate myocardin expression in rat VSMCs in vitro ( Figure 4E ).
An established model for VSMC phenotypic modulation in vitro involves treatment of VSMCs with PDGF-BB to induce SM gene downregulation and cell proliferation. 25 PDGF-BB is known to increase Sp-1 expression and activity, promoting its phosphorylation and nuclear localization. 22, 25 PDGF-BBactivated Sp-1 in turn increases the activity of KLF4 to repress myocardin, toggling SRF from the differentiation to the proliferative program of VSMCs. 22 As the differential effects of miR-133 on its own on SM genes and their transcriptional activators and coactivators may also be dependent on the culture in vitro conditions, we tested their interplay in adult rat aortic VSMCs treated with PDGF-BB, which is a proper stimulus to evaluate VSMC phenotypic switch in vitro.
PDGF-BB downregulated miR-133 expression ( Figure 4F ) and reduced the expression of Tagln1, Acta2, and Mhy11, inducing VSMC proliferation ( Figure 4G and 4H) . Importantly, adeno-miR-133 prevented PDGF-BB-induced Tagln1, Acta2, and Myh11 downregulation, reducing PDGF-BBdependent VSMC proliferation ( Figure 4G and 4H) . Also remarkably, miR-133 overexpression prevented PDGF-BBinduced Sp-1 and Klf4 upregulation and myocardin downregulation ( Figure 4I ). When Sp-1 mut was overexpressed in VSMCs, miR-133 was unable to prevent PDGF-BBdependent Klf-4 upregulation, as well as myocardin, Myh11, and Acta2 downregulation, in proliferating VSMCs in vitro ( Figure 4J and 4K) .
These data point to miR-133 preventing VSMC phenotypic switch in vitro by specifically repressing Sp-1 expression.
Adeno-miR-133 Transfection in the Rat Carotid Artery Reduces VSMC Phenotypic Switch and Proliferation After Balloon Injury In Vivo
After balloon injury in rats, VSMC activation in the vascular media layer reaches its peak at 2 days. [15] [16] At this time point, miR-133 levels were barely detectable in VSMCs of the media layer of injured arteries compared with the uninjured counterparts when evaluated by both quantitative reverse transcription-polymerase chain reaction and FISH ( Figure  5A and 5B). miR-133 began to increase in the media layer at 7 days after injury, when it was still absent in neointimal VSMCs ( Figure 5A and 5B). Finally, at 14 days, miR-133 was expressed in both medial and neointimal VSMCs ( Figure  5A and 5B). On the other hand, miR-1 levels remained unchanged in response to injury ( Figure 5A ).
Adeno-miR-133 or adeno-miR-1 were intraartery infused, as previously described. 8, 11 Carotid arteries of control rats were transfected with either an adeno-GFP, an adeno-empty, or just saline (labeled as CTRL unless otherwise specifically stated). Adeno-miR-133 transfection increased vascular miR-133 levels 48 hours following balloon injury compared with CTRL. Indeed, adeno-miR-133 normalized miR-133 expression in injured arteries to levels, similar to normal uninjured vessels ( Figure 5C ). Adeno-miR-1 successfully increased miR-1 vascular expression in injured vessels ( Figure 5C ).
In the carotid arteries treated with transfection of adenomiR-133, a significantly lower ratio of Ki-67-positive nuclei to total cells (proliferation indexϭ3Ϯ2%) was observed compared with CTRL carotid vessels (proliferation indexϭ16Ϯ3.5%; PϽ0.05), 2 days after balloon injury ( Figure  5D and 5E). No effects on VSMC proliferation were observed by the transfection of adeno-miR-1 ( Figure 5D ). Moreover, Sp-1 and moesin were upregulated in carotid arteries following vascular injury ( Figure 5F and 5G) compared with uninjured vessels in CTRL rats ( Figure 5F and 5G) . On the other hand, Sp-1 and moesin injury-induced vascular upregulation was inhibited by adeno-miR-133 treatment in agreement with the destabilizing influence of miRNAs on their specific targets ( Figure 5F and 5G) .
Thus, miR-133 inversely correlates with VSMC phenotypic switch and proliferation in injured vessels in vivo, and its forced expression reduces VSMC activation after vascular injury, where it negatively regulates the expression of its specific targets, Sp-1 and moesin.
miR-133 Plays a Pivotal Role in Regulating Neointimal Hyperplasia After Balloon Injury In Vivo
In CTRL rats (nϭ8), balloon injury of the carotid artery promoted after 14 days the generation of a thick neointima, which significantly reduced the lumen of the vessel ( Figure  6A to 6C). This response was nearly abolished by adenomiR-133 (nϭ7). Indeed, miR-133 overexpression significantly reduced neointimal hyperplasia (neointimal areaϭ 0.073Ϯ0.019 mm 2 , neointima/media ratioϭ0.498Ϯ0.137) 14 days after experimental balloon angioplasty, compared with CTRL groups (neointimal areaϭ0.178Ϯ0.023 mm 2 , neointima/media ratioϭ1.250Ϯ0.129) ( Figure 6A and 6B) . AdenomiR-1 (nϭ7) had no effect on neointimal formation (neointimal areaϭ0.180Ϯ0.035 mm 2 , neointima/media ratioϭ1.190Ϯ 0.168) ( Figure 6A and 6B) . In particular, the neointimal tissue of the injured carotid arteries was reduced by Ϸ60% in the rats transfected with adeno-miR-133, compared with CTRL ( Figure  6C ). The medial layer (0.143Ϯ0.014 mm 2 in CTRL) was not affected by adeno-miR-133 (0.149Ϯ0.013 mm 2 , Pϭnot significant), suggesting a normal arterial contractile state. Adeno-GFP (nϭ6) did not affect vascular remodeling per se at 14 days after balloon injury (neointimal areaϭ0.179Ϯ0.018 mm 2 , neointima/ media ratioϭ1.187Ϯ0.132) (Figure 6A to 6C) .
To substantiate the inhibitory role played by miR-133 on VSMC proliferation in vivo, we evaluated the effects of antagonizing endogenous miR-133 through the in vivo injection of a PBS-formulated locked-nucleic-acid-modified oligonucleotide to specifically suppress miR-133 (anti-miR-133). 26 On the basis of the time course of miR-133 vascular expression after balloon injury ( Figure 5A ), additional rats were implanted at 7 days after balloon injury with an osmotic pump (under the skin of the rat neck) to systemically release anti-miR-133 (30 mg/kg) from 7 to 14 days. To obtain an in situ time course of vascular cell proliferation within the vessel wall after injury, BrdU was administered intraperitoneally (30 mg/kg) 3 times every 8 hours before each rat euthanasia to label proliferating cells. BrdU-positive VSMCs reached their peak at 2 days and decreased from 7 to 14 days in the media layer, whereas they peaked at 7 days and decreased thereafter in the neointima layer of CTRL salinetreated animals (nϭ4 for each time point) ( Figure 7A and 7B). Anti-miR-133 systemic administration reduced vascular levels of miR-133 at 14 days after injury compared with CTRL ( Figure 7C ). Importantly, anti-miR-133 treatment (nϭ5) maintained BrdU-positive proliferating VSMCs, which were significantly increased in both media and neointimal layers compared with CTRL at 14 days ( Figure 7B ). The prolongation of VSMC proliferation by anti-miR-133 resulted in an increased neointimal formation at 14 days after injury (neointimal areaϭ0.255Ϯ0.036 mm 2 , neointima/media ratioϭ1.743Ϯ0.152) compared with untreated CTRL rats (nϭ7, neointimal areaϭ0.177Ϯ0.021 mm 2 , neointima/media ratioϭ1.198Ϯ0.132), reducing vessel lumen ( Figure 7D to 7F). PBS (saline) lone infusion through the osmotic pump in additional control animals (PBS, nϭ6) did not affect neointimal formation (neointimal areaϭ0.169Ϯ0.029 mm 2 , neointima/media ratioϭ1.14Ϯ0.143) (Figure 7D to 7F) .
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Discussion
This study is the first to document the presence of miR-133 in VSMCs and to reveal essential roles of this miRNA in the control of VSMC phenotypic switch in vitro and in vivo. Indeed, (1) miR-133 is robustly expressed in VSMCs to levels similar to other previously characterized vascular miRs, whereas the expression of its cognate bicistronic gene, miR-1, is negligible; (2) miR-133 but not miR-1 regulates VSMC growth state by inhibiting VSMC proliferation and migration in vitro; (3) miR-133 specifically targets for repression the transcription factor Sp-1, which mediates miR-133 inhibition of SM gene downregulation and VSMC proliferation in vitro; and (4) miR-133 is downregulated in proliferating VSMCs of carotid arteries in response to balloon injury in rats and adenoviral overexpression of miR-133 in the vascular wall reduces, whereas anti-miR-133 systemic treatment exacerbates VSMC hyperplasia after experimental balloon injury, pointing to a crucial role of miR-133 in regulating pathological vascular remodeling in vivo.
miR-143 and -145 are key players in SM differentiation program through the enhancement of myocardin expression/ activity by silencing the transcription factors Elk4 and Klf4. 7 miR-145 inhibits SM proliferation and neointima formation after vascular injury, directly repressing KLF5, which in turn regulates myocardin. 8 Furthermore, miR-145 plays a critical role in keeping the contractile functions of VSMCs and vessels through its regulation of the angiotensin-converting enzyme gene. 10 Finally, miR-143/145 knockout mice present severe structural modifications of the aorta, and accordingly, human aortic aneurysms are characterized by a significant reduced expression of miR-143/145, pointing to a specific role of this miRNA in vascular diseases. 9 In the present study, we have shown that miR-133 prevents smooth muscle phenotypic switch through direct repression of the transcription factor Sp-1, which is a known regulator of the Klf4/myocardin axis. Therefore, it highly tempting to speculate that a miRNA network involving miR-143/145 and miR-133 might exist to cooperatively regulate VSMC phenotypic switch in vitro and in vivo. miR-133 promotes myoblast growth, which suppresses differentiation, 4, 5 whereas it suppresses proliferation of cardiac myocytes by repressing cyclin D2 expression. 19 Here we show that miR-133 robustly decreases rat VSMC proliferation in vitro and following balloon injury in vivo. Also, we have data to show that miR-133 is able to replicate its effects in rat VSMCs also in human coronary-derived SMCs (Online Figure VI) . Therefore, miR-133 appears to have both positive and negative effects on proliferation, depending on the muscle cell type.
Bicistronic genes, such as miR-143/145 and miR-221/222, show similar changes in expression in the vessel wall. However, this was not the case for miR-1/miR-133, as VSMC miR-1 expression is very weak compared with miR-133. Accordingly, previous data show that miR-133 is downregulated in the carotid artery tissue subjected to damage, whereas miR-1 was not reported by the miRNA array as being negligible in the arterial wall. 6 However, no further analysis was performed to identify either the cellular specificity of miR-133 expression within the vessel wall or its function. Importantly, a differential expression for polycistronic mature miRNAs has already been reported for miR-21 and miR-17 to -92. 27 Another intriguing possibility is that miR-1 is actively extruded from VSMCs in a way similar to what happens for other miRs shuttled out of the cells through exosomes. 28 Two recent articles 12,13 support a molecular network whereby miR-1 is induced by myocardin overexpression to act as a self-limiting mechanism of myocardin in the regulation of SMC contraction. Indeed, miR-1 expression reduced the proliferation of myocardin-overexpressing human SMCs. However, miR-1 alone only slightly reduces human SMC growth in vitro, whereas anti-miR-1 in absence of myocardin overexpression does not have any effect on hSMC proliferation. Finally, miR-1 expression appears to be downregulated in the vascular wall of ligated common carotid vessels. The data above are only in part at odds with the findings of our present study. First, the data from Zheng group 12, 13 are consistent with our findings in showing minimal if not negligible levels of miR-1 in normal quiescent human SMCs. Second, miR-1 effects on human SMC proliferation are mainly secondary to myocardin overexpression. 12, 13 Third, in the latter 2 studies, 2 different human SMC lines were obtained through in vitro selection, which may have a role in the reported findings. Finally, it should be noted that we injured carotid vessel by balloon endothelial denudation and media injury which is different from the mouse carotid ligation model used by Chen et al. 13 Accordingly, the reduced expression of miR-1 in the vascular wall after carotid ligation cannot be accounted for by specific variation within SMCs, as it may depend on other cell types within the vessel tissue.
miRNAs mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Here, we showed that miR-133a suppresses the expression of the transcription factor Sp-1 and of the actinbinding protein moesin. In particular, for its central role in modulating VSMC phenotypic switch in vitro and in vivo, we have therefore focused our attention on Sp-1. Sp-1 is indeed a transcription factor activated by phenotypic switch promoting stimuli 1,3 on which it specifically binds the G/C suppressor cis-element located in MHY11 and TAGLN-1. 1,20 -22 Activated Sp-1 in turn increases the activity of Klf4, which represses myocardin and therefore downregulates most of the SM genes. 22, 25 Furthermore, Sp-1 binding to the G/C repressor element drives SM-gene downregulation after vascular injury in vivo. 25 Here, we show that Sp-1 repression by miR-133 is the dominant factor underlying miR-133 effects on SM gene regulation and VSMC proliferation in vitro (Figure 8 ). Indeed, miR-133 gain-and loss-of-function experiments in unstimulated VSMCs show that this miR robustly increases MHY11 (which is the most restricted SM gene) while mildly reducing ACTA2. Accordingly, miR-133 prevents PDGF-BB-induced downregulation of MHYC11, ACTA2, and TAGLN1 and VSCM proliferation in vitro. Importantly, when a mutated form of Sp-1, which cannot be targeted for repression by miR-133, is overexpressed in VSMCs, miR-133 loses its function of maintaining the molecular differentiation program and the cellular quiescent state.
A long-standing paradox in vascular biology is the double role of SRF both on VSMC proliferation and differentiation. 1, 3, 29 Indeed, SRF regulates growth-responsive genes, such as c-fos, but it also regulates virtually every SMCspecific gene. 1, 3, 29 Myocardin is the main SRF coactivator to direct SRF to function as a positive regulator of differentiation, competing with other SRF cofactors, such as Elk-1, Klf4, and others that promote SRF to function as a regulator of proliferation. 24 miR-133 is a direct transcriptional target of SRF. 4, 5 However, the genetic interaction between miR-133 and SRF constitutes a negative feedback loop in which the upregulation of miR-133 by SRF results in increased repres- sion of SRF. 4, 5 Here, we show that miR-133 reduces SRF levels in VSMCs in vitro (Figure 8 ). However, SRF levels are not crucial for SM gene regulation and VSMC proliferation. 1, 3, 29 More importantly, miR-133 targeting Sp-1, which is needed for Klf4 activation to downregulate myocardin, 22 prevents myocardin repression and VSMC proliferation on PDGF-BB stimulation in vitro.
Finally, the mechanisms regulating miR-133 expression in muscle cells are only partially known. Indeed, in cardiac and skeletal muscle cells, miR-133 is regulated by several transcription factors or kinases, such as MEF2, 30 myogenic regulatory factors, MAPK/ERK1/2, 17 and nuclear factor of activated T cells. 31 All of these factors are intertwined with SRF, 1,3 which, as mentioned above, regulates miR-133 expression. Accordingly, the present results suggest that MAPK/ERK1/2 is a critical upstream signaling pathway of miR-133 expression in VSMCs that is responsible for its downregulation when VSMCs are primed for the phenotypic switch in vitro.
